Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.
Hilger
R A
RA
Department of Internal Medicine (Cancer Research), University of Essen Medical School, West German Cancer Center, Essen, Germany. ralf.hilger@uni-essen.de
Kredtke
S
S
Scheulen
M E
ME
Seeber
S
S
Strumberg
D
D
D000328:Adult; D019540:Area Under Curve; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D003967:Diarrhea / Q000139:chemically induced; D004334:Drug Administration Schedule; D005076:Exanthema / Q000139:chemically induced; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010766:Phosphorylation / Q000187:drug effects; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000077157:Sorafenib
D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D019908:Proto-Oncogene Proteins c-raf